This trial shows that the RNS System for thalamic stimulation is safe and effective for reducing primary generalized seizures in individuals 12 years of age or older with drug-resistant idiopathic generalized epilepsy.
2 Primary · 1 Secondary · Reporting Duration: Implant through 2 years post-implant
Active Control
Non-Treatment Group
100 Total Participants · 2 Treatment Groups
Primary Treatment: Active Group (responsive stimulation ON) · Has Placebo Group · Phase 3
Age Any Age · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: